Company Overview
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -99.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -9.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -9.77% |
| 1 Year: | -99.80% |
Stock Price Performance
| 1 Year: | +628.38% |
| 6 Months: | +154.77% |
| 3 Months: | +303.93% |
| 1 Month: | +0.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)84.37 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -9.8% CAGR over 5 years.
- RSI at 84 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FBRX Forte Biosciences Inc R3KPHARMA | 76.99 | -16.85 | $1.63B | 0.00% | -113.91% | -62.28% | -9.77% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 10.00K | 10.00K | - | 9.00K | 9.00K | 18.01M | - | 9.00K | 9.00K | 9.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.12M | 11.58M | 18.38M | 24.57M | 22.44M |
| Operating Income | -7.57M | -7.62M | -8.53M | - | -8.55M | -8.65M | -9.74M | - | -12.85M | -15.33M | 1.43M | - | -16.87M | -629.00K | -684.00K | - | -2.03M | -34.75M | -5.01M | -4.74M | -5.75M | -7.70M | -2.51M | -3.02M | -3.42M | -6.86M | -9.03M | -10.22M | -7.80M | -12.82M | -8.63M | -16.12M | -11.58M | -18.38M | -24.57M | -22.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.11M | -11.56M | -18.37M | -24.55M | -22.42M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.66M | -11.25M | -17.68M | -23.75M | -21.76M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 373.00K |
| Net Income | -8.01M | -8.04M | -9.00M | -8.43M | -9.07M | -9.07M | -9.95M | -10.84M | -12.88M | -16.09M | -383.00K | -19.60M | -1.19M | -630.00K | -690.00K | -10.58M | -2.05M | -34.76M | -5.10M | -4.80M | -5.81M | -7.75M | -2.57M | -3.04M | -3.40M | -6.75M | -8.90M | -9.96M | -7.42M | -12.51M | -8.39M | -15.66M | -11.25M | -17.68M | -24.79M | -22.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.43 | -0.54 | -0.17 | -0.21 | -0.18 | -0.32 | -0.42 | -6.57 | -4.03 | -6.78 | -4.54 | -1.37 | -0.96 | -0.99 | - | -1.24 |
| R&D Expense | 6.47M | 6.53M | 7.59M | - | 6.62M | 6.63M | 7.56M | - | 10.44M | 12.76M | 12.26M | - | 12.43M | 11.97M | 13.29M | - | 3.14M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 49.00K | 41.00K | 18.04M | 36.00K | - | - | - | - | - | - |
| Operating Income | -22.95M | -31.69M | -37.63M | -45.85M | -4.06M | -46.28M | -21.49M | -13.90M | -32.49M | -36.60M | -70.66M |
| Net Income | -23.06M | -33.48M | -38.93M | -48.95M | -4.07M | -46.49M | -21.71M | -13.88M | -31.48M | -35.48M | -69.38M |
| Diluted EPS | - | - | - | - | - | - | -1.55 | -0.80 | -24.92 | -12.17 | -4.71 |
| R&D Expense | 19.17M | 27.22M | 29.11M | 51.08M | 45.30M | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 35.35M | 92.07M | 103.08M | 7.66M | 61.24M | 43.31M | 42.00M | 38.98M | 61.56M | 82.78M |
| Total Equity | -70.44M | -92.33M | -124.42M | 71.08M | -736.00K | -4.77M | 58.98M | 41.55M | 38.82M | 35.31M | 52.48M | 60.99M |
| Cash & Equivalents | 4.20M | 8.15M | 5.51M | 35.93M | 40.81M | 6.94M | 58.77M | 42.04M | 41.10M | 37.12M | 22.24M | 76.96M |
| Long Term Debt | - | - | 10.24M | 3.62M | 26.20M | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 28.36M | 20.99M | 44.94M | 17.31M | - | - | - | - | 9.08M | 21.79M |
| Current Liabilities | - | - | 14.38M | 17.33M | 16.53M | 1.91M | 2.26M | 1.76M | 3.18M | 3.67M | 9.08M | 20.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -29.54M | -31.13M | -34.47M | -2.77M | -18.42M | -16.68M | -8.19M | -28.71M | -30.75M | -50.88M |
| Investing Cash Flow | - | 24.57M | -27.71M | -4.19M | -162.00K | 3.58M | - | - | 47.00K | -35.99M | 36.23M |
| Financing Cash Flow | - | 2.33M | 89.26M | 43.54M | 4.86M | 66.67M | -44.00K | 7.24M | 24.68M | 51.86M | 69.36M |
| Capital Expenditure | -231.00K | -525.00K | -655.00K | -1.97M | -162.00K | - | - | - | -88.00K | -37.00K | -116.00K |
| Free Cash Flow | - | -30.06M | -31.79M | -36.44M | -2.93M | - | - | - | -28.79M | -30.78M | -51.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -64,673.5% | -91,775.6% | -254.2% | -11,288.9% | - | - | - | - | - | - |
| Net Margin % | - | -68,322.4% | -94,948.8% | -271.4% | -11,302.8% | - | - | - | - | - | - |
| ROE % | 25.0% | 26.9% | -54.8% | 6,651.5% | 85.3% | -78.8% | -52.2% | -35.8% | -89.1% | -67.6% | -113.7% |
| ROCE % | - | -151.1% | -50.3% | -53.0% | -70.7% | -78.5% | -51.7% | -35.8% | -92.0% | -69.7% | -113.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 9.94% | 2.11M | $162.49M |
| 2 | Orbimed Advisors LLC. | 7.43% | 1.58M | $121.47M |
| 3 | Fred Alger Management, LLC | 6.78% | 1.44M | $110.84M |
| 4 | Jupiter Topco LLC | 6.47% | 1.37M | $105.71M |
| 5 | Blackrock Inc. | 5.76% | 1.22M | $94.15M |
| 6 | Affinity Asset Advisors, Llc | 5.40% | 1.15M | $88.18M |
| 7 | MPM Bioimpact LLC | 4.65% | 987.45K | $76.02M |
| 8 | TCG Crossover Management, LLC | 4.33% | 920.00K | $70.83M |
| 9 | Vanguard Capital Management LLC | 4.06% | 861.74K | $66.35M |
| 10 | Woodline Partners LP | 3.36% | 712.75K | $54.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FBRX
Forte Biosciences, Inc. SEC Filing (Sep 8, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdjNOOVI5aG1iU0cwTnpsbF9pZjdTN2J3MjhfQWJiTDdlTGRTMHN0OXhsMm5BUWFTRFQzX1pjZGxrTzE4bkFuMXdVOVoxdnpMTERtdkd6VU16UXJPNlRWT1pFeHU4THBWS2YtRmxPZmdoQTZSNERoeThSOWYyM3RieGZ0ZXFrN280U0pyMl…
Forte Biosciences (FBRX) loses Federated Hermes as a shareholder - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPcDZnaGFVbzV5dEptb1VObGdEQW1JMGpmOGgtc3BOWGRqdGZQRUVhV3B4SnBEaUZTM3owNW1tR2FpRzNFT1VjN2hZTWxUd3NOMlRWdlNQczEzRDBGQ25QeU51VEFmSG4tOXI1OF9mdVlTVGhiekFOajYxTDZTOWRoaUtwQjlSM2cxYVhSWV…
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQODlEdDlsZF9aeFNjY3AyNlpSSTMzQXdQeUg2azRvLXZFWE1DZVNIclJ6eVFRbHNld214TzVGR09xYXhpSGxRMTdLblFDZE1aWE10SmZPbnNPVllTZ05hbWdLMVhreHBJdGNiRmhfZUlDel82ZzJNNFpHdTVDRVRXaksxZ05rN0RLcFdaUj…
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPLVF1SHliRjVhRW1DMWVkd0JHS1JPTVlaMDVVUUY0bTgtalY4UGstdk9RRjJfWG9CbGlqZVYxbjJseEdNS1E2cGFPZk5nbkF2dXA3UDZEODh3SFd0c2hDeGFERUZMNktZZzZpQ2ZUa3FqcFdnd3JXd0U0a2lyWkpjZEhWOGQxcVg1UWtTaj…
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPaHU0aGo3LWY3eDRjN1VNV0RJaDg0TERVYzBFYVFDdzlBRzY1TzN4SG1wNlVKRVcxMldEVVJhQnBCZFM1ZzZ0Yks4RTNNN2dlWGxSNXV1ZE5yT01INEphSjAxa3h4NXJOTk1ab0Q2dG54eFA1UGpoQXdHQlBIdXRyN29DaEJwU2tERkhtYz…
Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOUy1zelZzU1VYakZmbEIwQzRnWUhWMjRFZ2tOc1pWX3hSaTV5MzdXMElvSE9IXzl6VkRKSEFPZ2hZSmtKMFRob1pORGlDaXNaU3JORVFtc1U3c2s2cXhLR3F5dU1oMVRrNHlINDk3VXBBSURBYWZLV0F0OVpIX0RqYXUxRkpIY2F3cmcxVS…
FBRX — Frequently Asked Questions
What is the current share price of Forte Biosciences Inc (FBRX)?
As of 2026-09-19 21:16 PDT, Forte Biosciences Inc (FBRX) trades at $76.99 on NasdaqCM. Its 52-week range is $10.30 to $76.99.
What is the market capitalisation of FBRX?
Forte Biosciences Inc (FBRX) has a market capitalisation of $1.63B on NasdaqCM.
What is the P/E ratio of FBRX?
FBRX trades at a trailing price-to-earnings (P/E) ratio of -16.85. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 10.24.
What is the return on equity (ROE) of FBRX?
FBRX has a return on equity (ROE) of -62.28%. Its return on capital employed (ROCE) is -113.91%.
Is FBRX a good stock to buy?
This page provides a data-driven analysis of Forte Biosciences Inc (FBRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.